Somm E, Montandon SA, Loizides-Mangold U, Gaia N, Lazarevic V, De Vito C, et al
Ong ES, Oh CL, Tan JC, et al
The case was brought by the Outsourcing Facilities Association (OFA), a trade group that represents FDA-sanctioned compounding pharmacies, which said that ending the shortage was a reckless and arbitrary decision. The plaintiff also alleged that the FDA made its move to benefit special interests, raise drug prices, and deprive much of the public access to a needed medicine. Pittman did not buy these arguments, but with his ruling filed under seal, his exact reasoning for denying the injunction is unknown
As with nearly any emerging field of study, there are methodological inconsistencies which can significantly impact measures of analyte(s)
No comment from NovoNordisk at this time
Tuberous sclerosis complex and epilepsy: recent developments and future challenges